Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 23 von 288
Pharmacological research, 2020-10, Vol.160, p.105018-105018, Article 105018
2020
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs
Ist Teil von
  • Pharmacological research, 2020-10, Vol.160, p.105018-105018, Article 105018
Ort / Verlag
Elsevier Ltd
Erscheinungsjahr
2020
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
  • [Display omitted] Stroke is a major cause of mortality and morbidity worldwide. Considerable experimental and clinical evidence suggests that both diabetes mellitus (DM) and post-stroke hyperglycemia are associated with increased mortality rate and worsened clinical conditions in acute ischemic stroke (AIS) patients. Insulin treatment does not seem to provide convincing benefits for these patients, therefore prompting a change of strategy. The selective agonists of Glucagon-Like Peptide-1 Receptors (GLP-1Ras) and the Inhibitors of Dipeptidyl Peptidase-IV (DPP-IVIs, gliptins) are two newer classes of glucose-lowering drugs used for the treatment of DM. This review examines in detail the rationale for their development and the physicochemical, pharmacokinetic and pharmacodynamic properties and clinical activities. Emphasis will be placed on their neuroprotective effects at cellular and molecular levels in experimental models of acute cerebral ischemia. In perspective, an adequate basis does exist for a novel therapeutic approach to hyperglycemia in AIS patients through the additive treatment with GLP-1Ras plus DPP-IVIs.
Sprache
Englisch
Identifikatoren
ISSN: 1043-6618
eISSN: 1096-1186
DOI: 10.1016/j.phrs.2020.105018
Titel-ID: cdi_proquest_miscellaneous_2416943844

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX